Get started
Author

Julia D. Maltzman

SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
2017 · Ruben A. Mesa, Jean-Jacques Kiladjian, et al. · Journal of Clinical Oncology · 389
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
2017 · Claire N Harrison, Alessandro M Vannucchi, et al. · The Lancet Haematology · 321
Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
2014 · Raffit Hassan, Hedy L. Kindler, et al. · Clinical Cancer Research · 180
Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease
2012 · Daniel J O’Shannessy, Elizabeth B Somers, et al. · SpringerPlus · 155
PDF
Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
2015 · Brian M. Necela, Jennifer A. Crozier, et al. · PLoS ONE · 146
PDF
Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
2018 · Manish A. Shah, Alexander Starodub, et al. · Clinical Cancer Research · 95
Significance of Folate Receptor Alpha and Thymidylate Synthase Protein Expression in Patients with Non–Small-Cell Lung Cancer Treated with Pemetrexed
2012 · Daniel C. Christoph, Bernadette Reyna Asuncion, et al. · Journal of Thoracic Oncology · 83
A phase 2 study of simtuzumab in patients with primary, post‐polycythaemia vera or post‐essential thrombocythaemia myelofibrosis
2017 · Srdan Verstovsek, Michael R. Savona, et al. · British Journal of Haematology · 49
Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) imaging
2015 · Liza Lindenberg, Anish Thomas, et al. · Oncotarget · 47
PDF
A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia
2017 · Srdan Verstovsek, Stephane Courby, et al. · Leukemia Research · 44
PDF
Farletuzumab in lung cancer
2013 · Anish Thomas, Julia Maltzman, et al. · Lung Cancer · 27
Correction: Folate Receptor-α (FOLR1) Expression and Function in Triple Negative Tumors
2015 · Brian M. Necela, Jennifer A. Crozier, et al. · PLoS ONE · 22
PDF
Population pharmacokinetics and exposure–response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection
2016 · Anubha Gupta, Ziad Hussein, et al. · Cancer Chemotherapy and Pharmacology · 18
Phase 3 randomized trial of momelotinib (MMB) versus best available therapy (BAT) in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX).
2017 · Claire N. Harrison, Alessandro M. Vannucchi, et al. · Journal of Clinical Oncology · 16
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
2017 · Johanna C. Bendell, Alexander Starodub, et al. · Journal of Clinical Oncology · 16
Assessment of Folate Receptor-α and Epidermal Growth Factor Receptor Expression in Pemetrexed-Treated Non–Small-Cell Lung Cancer Patients
2014 · Daniel C. Christoph, Bernadette Reyna-Asuncion, et al. · Clinical Lung Cancer · 15
Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC.
2020 · Alexandra Drakaki, Arash Rezazadeh Kalebasty, et al. · Journal of Clinical Oncology · 13
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
2017 · Johanna C. Bendell, Alexander Starodub, et al. · Journal of Clinical Oncology · 8
Phase 3 trial of momelotinib (MMB) vs ruxolitinib (RUX) in JAK inhibitor (JAKi) naive patients with myelofibrosis (MF).
2017 · Ruben A. Mesa, Jean-Jacques Kiladjian, et al. · Journal of Clinical Oncology · 7
Results of a phase I study of GS-5745 in combination with mFOLFOX in patients with advanced unresectable gastric / GE junction tumors.
2016 · Manish A. Shah, Alexander Starodub, et al. · Journal of Clinical Oncology · 7
A phase II, open-label, randomized study to evaluate the efficacy and safety of GS-5745 combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.
2017 · Manish A. Shah, Jean-Philippe Metges, et al. · Journal of Clinical Oncology · 5
Evaluating collagen neoepitopes as pharmacodynamic biomarkers of GS-5745, an MMP9 inhibitor, in advanced gastric cancer.
2017 · Carrie Baker Brachmann, Yafeng Zhang, et al. · Journal of Clinical Oncology · 5
Updated results of a phase 1 study combining the matrix metalloproteinase 9 inhibitor GS-5745 and mFOLFOX6 in patients with advanced gastric/gastroesophageal junction cancer.
2017 · Manish A. Shah, Alexander Starodub, et al. · Journal of Clinical Oncology · 5
A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
2016 · Johanna C. Bendell, Alexander Starodub, et al. · Journal of Clinical Oncology · 5
Increased expression of folate receptor-α (FRA) in triple-negative breast cancer: A potential therapeutic target.
2013 · Jennifer A. Crozier, Brian M. Necela, et al. · Journal of Clinical Oncology · 5
Works count: 46
Citation count: 1,690
H-index: 15
I10-index: 17
Year
Topic
Type